title: Pegylated liposomal doxorubicin in ovarian cancer.
abstract: The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enhanced uptake by cancer cells. These properties translate into clinical utility in recurrent ovarian cancer as demonstrated by phase II and III trials, this proven clinical efficacy leading to FDA approval in second-line therapy for ovarian cancer. New combinations with cytotoxics, in particular with carboplatin, have demonstrated an acceptable toxicity profile and clinical utility in platinum-sensitive ovarian cancer. A favorable toxicity profile renders liposomal doxorubicin an ideal partner for combination regimens with other cytotoxics, and more recently with biological agents. Such combinations are the subject of ongoing clinical trials.
authors.affiliation: Department of Medicine.
authors.forename: Robert
authors.initials: R
authors.lastname: Strother
authors.forename: Daniela
authors.initials: D
authors.lastname: Matei
references.citation: Ann Intern Med. 1984 Dec;101(6):798-9
references.pmid: 6497196
references.citation: Cancer Chemother Pharmacol. 1999;44(4):303-6
references.pmid: 10447577
references.citation: Int J Gynecol Cancer. 2006 Jan-Feb;16(1):65-70
references.pmid: 16445612
references.citation: J Clin Oncol. 1995 Jul;13(7):1777-85
references.pmid: 7602367
references.citation: Gynecol Oncol. 2005 Aug;98(2):267-73
references.pmid: 15975643
references.citation: Cancer Res. 1994 Feb 15;54(4):987-92
references.pmid: 8313389
references.citation: Clin Pharmacokinet. 2003;42(5):419-36
references.pmid: 12739982
references.citation: Oncology. 2009;76(1):49-54
references.pmid: 19039248
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1419-25
references.pmid: 19224846
references.citation: Clin Cancer Res. 2000 Jun;6(6):2528-37
references.pmid: 10873109
references.citation: Ann Oncol. 2006 Jan;17(1):93-6
references.pmid: 16282248
references.citation: Anticancer Res. 2008 Mar-Apr;28(2B):1329-34
references.pmid: 18505074
references.citation: Oncology. 2002;62(3):216-22
references.pmid: 12065868
references.citation: Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34
references.pmid: 11702367
references.citation: Eur J Dermatol. 2008 Sep-Oct;18(5):566-70
references.pmid: 18693162
references.citation: Ann Oncol. 2004 Oct;15(10):1566-73
references.pmid: 15367419
references.citation: Ann Oncol. 2005 Feb;16(2):300-6
references.pmid: 15668288
references.citation: Gynecol Oncol. 2007 Dec;107(3):518-25
references.pmid: 17910981
references.citation: BMC Cancer. 2006 Aug 01;6:202
references.pmid: 16882344
references.citation: J Control Release. 1998 Apr 30;53(1-3):275-9
references.pmid: 9741935
references.citation: Eur J Cancer Clin Oncol. 1989 Dec;25(12):1795-803
references.pmid: 2632261
references.citation: Gynecol Oncol. 2007 Aug;106(2):375-80
references.pmid: 17512575
references.citation: Gynecol Oncol. 2001 May;81(2):206-12
references.pmid: 11330951
references.citation: Ann Oncol. 2007 Feb;18(2):263-8
references.pmid: 17108151
references.citation: Gynecol Oncol. 2004 May;93(2):513-6
references.pmid: 15099971
references.citation: Proc Natl Acad Sci U S A. 1988 Sep;85(18):6949-53
references.pmid: 3413128
references.citation: J Pharmacol Exp Ther. 1997 Mar;280(3):1319-27
references.pmid: 9067319
references.citation: J Control Release. 2006 Oct 27;115(3):251-8
references.pmid: 17045355
references.citation: Gynecol Oncol. 2006 Feb;100(2):318-23
references.pmid: 16239023
references.citation: Clin Cancer Res. 1999 Nov;5(11):3645-52
references.pmid: 10589782
references.citation: Ann Biol Clin (Paris). 1993;51(9):811-3
references.pmid: 8166395
references.citation: Ann Pharmacother. 2004 Jul-Aug;38(7-8):1212-4
references.pmid: 15161947
references.citation: Ann Oncol. 2003 Sep;14(9):1406-11
references.pmid: 12954580
references.citation: Am J Clin Oncol. 2006 Aug;29(4):399-404
references.pmid: 16891870
references.citation: Lancet. 1981 Aug 1;2(8240):241-6
references.pmid: 6114292
references.citation: Gynecol Oncol. 2008 Jan;108(1):90-4
references.pmid: 17949799
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3919-26
references.pmid: 15173101
references.citation: Gynecol Oncol. 2004 Oct;95(1):1-8
references.pmid: 15385103
references.citation: Ann Oncol. 2007 Jul;18(7):1159-64
references.pmid: 17229768
references.citation: Biochim Biophys Acta. 1990 Nov 16;1029(2):285-94
references.pmid: 2245212
references.citation: Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90
references.pmid: 15717738
references.citation: J Am Acad Dermatol. 2008 Feb;58(2 Suppl):S44-6
references.pmid: 18191705
references.citation: Cancer. 2003 Aug 1;98(3):610-7
references.pmid: 12879480
references.citation: Biochim Biophys Acta. 2004 May 27;1663(1-2):167-77
references.pmid: 15157619
references.citation: Anticancer Res. 2003 Jul-Aug;23(4):3543-8
references.pmid: 12926104
references.citation: Clin Pharmacokinet. 1988 Jul;15(1):15-31
references.pmid: 3042244
references.citation: Gynecol Oncol. 2000 Aug;78(2):143-7
references.pmid: 10926793
references.citation: J Am Acad Dermatol. 2008 May;58(5 Suppl 1):S84-7
references.pmid: 18489055
references.citation: Gynecol Oncol. 2004 Jul;94(1):147-51
references.pmid: 15262133
references.citation: Cancer Res. 1982 Nov;42(11):4734-9
references.pmid: 7127308
references.citation: Lancet. 1987 Sep 12;2(8559):624-5
references.pmid: 2887906
references.citation: Cancer Chemother Pharmacol. 2008 Apr;61(4):695-702
references.pmid: 17549475
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2811-8
references.pmid: 17602086
references.citation: J Clin Oncol. 2001 Jul 15;19(14):3312-22
references.pmid: 11454878
references.citation: Oncologist. 2007 Jan;12(1):72-8
references.pmid: 17227902
references.citation: Ann Oncol. 2006 Jun;17(6):957-61
references.pmid: 16600975
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5912-9
references.pmid: 16115933
references.citation: Cancer. 2002 Nov 15;95(10):2223-9
references.pmid: 12412177
references.citation: Gynecol Oncol. 2006 Oct;103(1):212-8
references.pmid: 16677696
references.citation: J Pharmacol Sci. 2004 Jul;95(3):381-9
references.pmid: 15272215
references.citation: Gynecol Oncol. 2007 Jul;106(1):164-9
references.pmid: 17481704
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Am J Clin Oncol. 2008 Oct;31(5):476-80
references.pmid: 18838885
references.citation: Anticancer Drugs. 2003 Sep;14(8):633-8
references.pmid: 14501385
references.citation: Cancer. 2000 Sep 1;89(5):1037-47
references.pmid: 10964334
references.citation: Br J Cancer. 2003 Oct 6;89(7):1180-4
references.pmid: 14520442
references.citation: Eur J Cancer. 2002 Oct;38(15):1992-7
references.pmid: 12376203
references.citation: Cancer Invest. 2005;23(8):665-70
references.pmid: 16377584
references.citation: Gynecol Oncol. 2005 May;97(2):374-8
references.pmid: 15863132
references.citation: Int J Clin Oncol. 2008 Apr;13(2):156-60
references.pmid: 18463961
references.citation: Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72
references.pmid: 10985896
references.citation: Int J Gynecol Cancer. 2007 May-Jun;17(3):589-94
references.pmid: 17300679
references.citation: Anticancer Res. 2006 Jan-Feb;26(1B):745-50
references.pmid: 16739347
references.citation: Int J Clin Oncol. 2008 Aug;13(4):330-4
references.pmid: 18704633
references.citation: Gynecol Oncol. 2002 Apr;85(1):136-9
references.pmid: 11925133
references.citation: Br J Clin Pharmacol. 2000 Oct;50(4):315-24
references.pmid: 11012554
references.citation: Int J Gynecol Cancer. 2008 Mar-Apr;18(2):223-7
references.pmid: 17511800
references.citation: Ann Intern Med. 1979 Nov;91(5):710-7
references.pmid: 496103
references.citation: Invest New Drugs. 2006 Sep;24(5):413-21
references.pmid: 16763786
references.citation: Gynecol Oncol. 2006 Oct;103(1):72-4
references.pmid: 16494932
references.citation: Cancer Invest. 2004;22(5):663-9
references.pmid: 15581046
references.citation: J Clin Oncol. 2008 Feb 20;26(6):890-6
references.pmid: 18281662
references.citation: Cancer Chemother Pharmacol. 1979;3(2):81-5
references.pmid: 389479
references.citation: Cancer Res. 1982 Apr;42(4):1412-22
references.pmid: 7060015
references.citation: Oncology. 2005;69(6):463-9
references.pmid: 16374040